Tag: VTE

The risk of venous thromboembolism (VTE) is significantly increased in patients with active cancer. While parenteral prophylactic anticoagulation has been shown to reduce the risk of VTE in cancer patients, its use is associated with an increased risk of major bleeding and the inconvenience of daily injections. Direct oral...

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer The risk of venous thromboembolism (VTE) is significantly increased in patients with active cancer. While parenteral prophylactic anticoagulation has been shown to reduce the risk of VTE in cancer patients, its use is associated with an increased risk of major bleeding...

Feb 21st - Dabigatran also has a significantly lower incidence of major bleeding events vs. warfarin. Image: PD 1. Long term treatment with dabigatran is noninferior to warfarin and superior to placebo at preventing recurrent or fatal venous thromboemobolism (VTE) after 3 months of initial treatment. 2. Dabigatran has significantly lower incidence...